These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 33849729)

  • 21. Reply to Lu Yang, Shi Qiu and Qiang Wei's Letter to the Editor re: Christopher E. Bayne, Stephen B. Williams, Matthew R. Cooperberg, et al. Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives. Eur Urol 2016;69:775-87.
    Bayne CE; Williams -B; Chapin BF
    Eur Urol; 2017 Feb; 71(2):e51. PubMed ID: 27461403
    [No Abstract]   [Full Text] [Related]  

  • 22. Reply to Finn E. von Eyben, Irene Virgolini and Giandomenico Roviello's Letter to the Editor re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol 2018;73:178-211.
    Gillessen S; de Bono JS; Sartor O; Omlin AG
    Eur Urol; 2018 Feb; 73(2):e32-e33. PubMed ID: 28869069
    [No Abstract]   [Full Text] [Related]  

  • 23. Reply to Piet R. Dirix, Carole Mercier, and Luc Y. Dirix's Letter to the Editor re: Fabian Lohaus, Klaus Zöphel, Steffen Löck, et al. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease? Eur Urol 2019;75:548-51.
    Hölscher T; Lohaus F; Wirth M; Troost EGC
    Eur Urol; 2019 Oct; 76(4):e103-e104. PubMed ID: 31256943
    [No Abstract]   [Full Text] [Related]  

  • 24. Reply to Chen Cheng, Sunxiang Ma, and Yang Liu's Letter to the Editor re: Dan Wood, Andrew Baird, Luca Carmignani, et al. Lifelong Congenital Urology: The Challenges for Patients and Surgeons. Eur Urol 2019;75:1001-7.
    Wood D; Baird A; Carmignani L; De Win G; Hoebeke P; Holmdahl G; Manzoni G; Nijman RJM; Taylor C; Tekgul S
    Eur Urol; 2019 Oct; 76(4):e94-e95. PubMed ID: 31327638
    [No Abstract]   [Full Text] [Related]  

  • 25. Reply to Bora Lee and Jae Heon Kim's Letter to the Editor re: Alan D. Uren, Nikki Cotterill, Christopher Harding, et al. Qualitative Exploration of the Patient Experience of Underactive Bladder. Eur Urol 2017;72:402-7.
    Uren AD; Cotterill N; Harding C; Hillary C; Chapple C; Klaver M; Bongaerts D; Hakimi Z; Abrams P
    Eur Urol; 2018 Jan; 73(1):e15-e16. PubMed ID: 28801128
    [No Abstract]   [Full Text] [Related]  

  • 26. Reply to Michael Froehner, Rainer Koch, Manfred P. Wirth's Letter to the Editor re: Jesse D. Sammon, Firas Abdollah, Anthony D'Amico, et al. Predicting Life Expectancy in Men Diagnosed with Prostate Cancer. Eur Urol 2015;68:756-65.
    Sammon JD; Abdollah FA; Trinh QD
    Eur Urol; 2016 Jun; 69(6):e129. PubMed ID: 26461111
    [No Abstract]   [Full Text] [Related]  

  • 27. Reply to Runqiang Yuan and Hongxing Huang's Letter to the Editor re: Ernesto R. Cordeiro Feijoo, Arjun Sivaraman, Eric Barret, et al. Focal High-intensity Focused Ultrasound Targeted Hemiablation for Unilateral Prostate Cancer: A Prospective Evaluation of Oncologic and Functional Outcomes. Eur Urol 2016;69:214-20.
    Sivaraman A; Barret E
    Eur Urol; 2017 May; 71(5):e148-e149. PubMed ID: 28161029
    [No Abstract]   [Full Text] [Related]  

  • 28. Reply to Erik Rud, Peter Lauritzen, and Eduard Baco's Letter to the Editor re: Henrik Grönberg, Martin Eklund, Wolfgang Picker, et al. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. Eur Urol 2018;74:722-8.
    Eklund M; Ström P; Grönberg H; Nordström T
    Eur Urol; 2019 Apr; 75(4):e104-e105. PubMed ID: 30514569
    [No Abstract]   [Full Text] [Related]  

  • 29. Reply to Zhipeng Mai's Letter to the Editor re: Taimur T. Shah, Max Peters, David Eldred-Evans, et al. Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. Eur Urol 2019;76:98-105.
    Shah TT; Peters M; Arya M; Ahmed HU
    Eur Urol; 2019 Sep; 76(3):e63-e64. PubMed ID: 31153649
    [No Abstract]   [Full Text] [Related]  

  • 30. Reply to John T. Leppert and James D. Brooks' Letter to the Editor re: Brandon A. Mahal, David D. Yang, Natalie Q. Wang, et al. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol 2018;74:146-54.
    Mahal BA; Yang DD; Nguyen PL
    Eur Urol; 2018 Nov; 74(5):e112-e113. PubMed ID: 30029822
    [No Abstract]   [Full Text] [Related]  

  • 31. Reply to Joe O'Sullivan, Daniel Heinrich, Nicholas D. James, et al.'s Letter to the Editor re: The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer. Eur Urol 2019;75:e51-2.
    On Behalf Of Ema
    Eur Urol; 2019 Mar; 75(3):e53. PubMed ID: 30658854
    [No Abstract]   [Full Text] [Related]  

  • 32. Reply to Weigang Yan, Zhien Zhou, Hanzhong Li's Letter to the Editor re: Jeffrey J. Tosoian, Debasish Sundi, Bruce J. Trock, et al. Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery. Eur Urol 2016;69:576-81.
    Tosoian JJ; Trock BJ; Ballentine Carter H; Mamawala M
    Eur Urol; 2017 Jan; 71(1):e13. PubMed ID: 27311363
    [No Abstract]   [Full Text] [Related]  

  • 33. Reply to Bernard Tombal's letter to the editor re: Alessandro Sciarra, Per Anders Abrahamsson, Maurizio Brausi, et al. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol 2013;64:722-30.
    Sciarra A
    Eur Urol; 2014 Apr; 65(4):e57. PubMed ID: 24388442
    [No Abstract]   [Full Text] [Related]  

  • 34. Reply to Chris Parker, Matthew R. Sydes and Howard Kynaston's letter to the editor re: Firas Abdollah, Nazareno Suardi, Cesare Cozzarini, et al. Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. Eur Urol 2013;63:998-1008.
    Abdollah F; Briganti A
    Eur Urol; 2013 Nov; 64(5):e103-4. PubMed ID: 23915876
    [No Abstract]   [Full Text] [Related]  

  • 35. Reply to Mengxin Lu, Yi Zhang, Yu Xiao's Letter to the Editor, re: Kimmo Kettunen, Peter J. Boström, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol 2019;76:430-4.
    Kettunen K; Boström PJ; Taimen P
    Eur Urol; 2019 Nov; 76(5):e137-e138. PubMed ID: 31420250
    [No Abstract]   [Full Text] [Related]  

  • 36. Reply to Michael Froehner and Christian Thomas's Letter to the Editor re: Sebastian Berg, Alexander P. Cole, Marieke J. Krimphove, et al. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. Eur Urol 2019;75:552-5.
    Berg S; Cole A; Trinh QD
    Eur Urol; 2019 Sep; 76(3):e76-e77. PubMed ID: 31174890
    [No Abstract]   [Full Text] [Related]  

  • 37. Reply to Francesco Montorsi and Giorgio Gandaglia's letter to the editor re: Georgios Gakis, Stephen A. Boorjian, Alberto Briganti, et al. The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature. Eur urol 2014;66:191-9.
    Gakis G; Stief CG
    Eur Urol; 2014 Dec; 66(6):e109-10. PubMed ID: 25204223
    [No Abstract]   [Full Text] [Related]  

  • 38. Reply to Alessia Cimadamore, Marina Scarpelli, Liang Cheng, et al's Letter to the Editor, re: Maria Chiara Sighinolfi, Bernardo Rocco's Words of Wisdom re: EAU Guidelines: Prostate Cancer 2019. Mottet N, van den Bergh RCN, Briers E, et al. https://uroweb.org/guideline/prostate-Cancer/. Eur Urol 2019, 76:871.
    Sighinolfi MC; Rocco B
    Eur Urol; 2020 May; 77(5):e128-e129. PubMed ID: 32067794
    [No Abstract]   [Full Text] [Related]  

  • 39. Reply to Jon Mikel Inarritu, Daniele Castellani, and Jeremy Y.C. Teoh's Letter to the Editor re: Agustina Bessa, Steven Maclennan, Deborah Enting, et al. Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method. Eur Urol 2019;76:260-1.
    Bessa A; Maclennan S; Enting D; Bryan R; Häggström C; Van Hemelrijck M
    Eur Urol; 2019 Aug; 76(2):e45-e46. PubMed ID: 31109813
    [No Abstract]   [Full Text] [Related]  

  • 40. Reply to Xueliang Zhou and Xinwei Han's Letter to the Editor re: Thomas Van den Broeck, Roderick C.N. van den Bergh, Nicolas Arfi, et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. Eur Urol 2019;75:967-87.
    Van den Broeck T; Mottet N; Lam T
    Eur Urol; 2019 Jul; 76(1):e16. PubMed ID: 30967298
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.